Palatine-based Acura Pharmaceuticals announced that Nexafed pseudoephedrine hydrochloride, its next generation pseudoephedrine with abuse deterrent technology, will now be stocked by Rite Aid pharmacies.
Nexafed is a 30 mg immediate-release pseudoephedrine product that combines effective nasal-congestion relief with a unique technology that disrupts the conversion of pseudoephedrine into the drug methamphetamine. Meth production and abuse is a growing problem in communities nationwide.
The next generation Nexafed tablet combines effective nasal-congestion relief with Impede technology, a unique polymer matrix that disrupts the conversion of pseudoephedrine into methamphetamine. Specifically, the Impede technology forms a thick gel when the tablets are dissolved in solvents typically used in the pseudoephedrine extraction or methamphetamine production processes, trapping the pseudoephedrine or converted methamphetamine to prevent its isolation or purification.
Acura Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development and commercialization of product candidates intended to address medication abuse and misuse.